Recent developments in the treatment of adult atopic dermatitis

Australasian Journal of Dermatology

Volumn 47, Issue 2, 2006, Pages 84-89

  Pua, Vernon S C ^a   Barnetson, Ross St C ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Basimixilab; Eczema; Infliximab; Intravenous immunoglobulin; Leflunomide; Montelukast; Pimecrolimus; Recombinant interferon ; Tacrolimus; Zafirlukast

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CETIRIZINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; EMOLLIENT AGENT; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIVER ENZYME; METHOTREXATE; MONOCLONAL ANTIBODY; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PARACETAMOL; PIMECROLIMUS; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON; TSUKUBAENOLIDE; ZAFIRLUKAST; ZILEUTON;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ASEPTIC MENINGITIS; ASTHMA; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; CANCER; CANCER RISK; CATARACT; CHEST TIGHTNESS; CHILL; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ENZYME BLOOD LEVEL; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; INFECTION RISK; LEUKOPENIA; LIVER TOXICITY; LOW BACK PAIN; LYMPHOMA; MOOD CHANGE; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOPENIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PHARYNGITIS; REBOUND; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BURNING SENSATION; SKIN CANCER; SKIN DEFECT; SKIN INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; TACHYPHYLAXIS; TELANGIECTASIA; TOPICAL TREATMENT; TREATMENT INDICATION; TREMOR; TUBERCULOSIS; VOMITING; WHEEZING;

ANTIBODIES, MONOCLONAL; CALCINEURIN; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; ISOXAZOLES; KERATOLYTIC AGENTS; LEUKOTRIENE ANTAGONISTS;

EID: 33645516186     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2006.00237.x     Document Type: Review

References (72)

1. Novak N Bieber T Leung DY. Immune mechanisms leading to atopic dermatitis. J. Allergy Clin. Immunol. 2003 112 S128 39.
2. Leung DY Bieber T. Atopic dermatitis. Lancet 2003 361 151 60.
3. Finlay AY. Quality of life in atopic dermatitis. J. Am. Acad. Dermatol. 2001 45 S64 6.
4. Herd RM Tidman MJ Prescott RJ Hunter JA. The cost of atopic eczema. Br. J. Dermatol. 1996 135 20 3.
5. Williams H Robertson C Stewart A Ait-Khaled N Anabwani G Anderson R et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J. Allergy Clin. Immunol. 1999 103 125 38.
6. Foley P Zuo Y Plunkett A Marks R. The frequency of common skin conditions in preschool-age children in Australia: atopic dermatitis. Arch. Dermatol. 2001 137 293 300.
7. Marks R Kilkenny M Plunkett A Merlin K. The prevalence of common skin conditions in Australian school students: 2. Atopic dermatitis. Br. J. Dermatol. 1999 140 468 73.
8. Williams HC. Epidemiology of atopic dermatitis. Clin. Exp. Dermatol. 2000 25 522 9.
9. Barnetson RS Gawkrodger DJ. Eczema and contact dermatitis - pathophysiology. In Holgate ST Church MK (eds). Allergy. London Gower Medical Publishing 1993 23.1 10.
10. Alomar A Berth-Jones J Bos JD Giannetti A Reitamo S Ruzicka T Stalder JF Thestrup-Pedersen K (European Working Group on Atopic Dermatitis). The role of topical calcineurin inhibitors in atopic dermatitis. Br. J. Dermatol. 2004 151 3 27.
11. Eichenfield LF Hanifin JM Beck LA Lemanske RF Jr Sampson HA Weiss ST Leung DY. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003 111 608 16.
12. Akhavan A Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin. Dermatol. 2003 21 225 40.
13. van Joost T Heule F Korstanje M van den Broek MJ Stenveld HJ van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br. J. Dermatol. 1994 130 634 40.
14. Sowden JM Berth-Jones J Ross JS Motley RJ Marks R Finlay AY Salek MS Graham-Brown RA Allen BR Camp RD. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991 338 137 40.
15. Berth-Jones J Takwale A Tan E Barclay G Agarwal S Ahmed I Hotchkiss K Graham-Brown RA. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br. J. Dermatol. 2002 147 324 30.
16. Kuanprasert N Herbert O Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas. J. Dermatol. 2002 43 125 7.
17. Grundmann-Kollmann M Korting HC Behrens S Leiter U Krahn G Kaufmann R Peter RU Kerscher M. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br. J. Dermatol. 1999 141 175 6.
18. Grundmann-Kollmann M Podda M Ochsendorf F Boehncke WH Kaufmann R Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch. Dermatol. 2001 137 870 3.
19. Benez A Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br. J. Dermatol. 2001 144 638 9.
20. Novak N Kwiek B Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin. Exp. Dermatol. 2005 30 160 4.
21. Stuetz A Grassberger M Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981). Semin. Cutan. Med. Surg. 2001 20 233 41.
22. Haniffin JM Ling MR Langley R Breneman D Rafal E and the Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I efficacy. J. Am. Acad. Dermatol. 2001 44 S28 38.
23. Soter NA Fleischer AB Jr Webster GF Monroe E Lawrence I and the Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II safety. J. Am. Acad. Dermatol. 2001 44 S39 46.
24. Ashcroft DM Dimmock P Garside R Stein K Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005 330 516 24.
25. Reitamo S Wollenberg A Schopf E Perrot JL Marks R Ruzicka T et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch. Dermatol. 2000 136 999 1006.
26. Reitamo S Rustin M Ruzicka T Cambazard F Kalimo K Friedmann PS et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol. 2002 109 547 55.
27. Reitamo S. 0.1% Tacrolimus ointment is an effective treatment for adults with moderate or severe atopic dermatitis. J. Eur. Acad. Dermatol. Venereol 2003 17 Suppl. 3 308.
28. Pacor ML Di Lorenzo G Martinelli N Mansueto P Rini GB Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin. Exp. Allergy 2004 34 639 45.
29. Meurer M Folster-Holst R Wozel G Weidinger G Juenger M Braeutigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 271 7.
30. Meurer M Fartasch M Albrecht G Vogt T Worm M Ruzicka T et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004 208 365 72.
31. Luger T Van Leent EJ Graeber M Hedgecock S Thurston M Kandra A et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. 2001 144 788 94.
32. Kyllonen H Remitz A Mandelin JM Elg P Reitamo S. Effects of 1 year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br. J. Dermatol. 2004 150 1174 81.
33. Van Leent EJ Ebelin ME Burtin P Dorobek B Spuls PI Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel) SDZ ASM 981, in patients with atopic dermatitis. Dermatology 2002 204 63 8.
34. Carucci J Washenik K Weinstein A Shupack J Cohen D. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch. Dermatol. 1998 134 758 68.
35. Kagi M. Leukotriene receptor antagonists - a novel therapeutic approach in atopic dermatitis? Dermatology 2001 203 280 3.
36. Zabawski EJ Kahn MA Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol. Online J. 1999 5 10.
37. Woodmansee DP Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann. Allergy Asthma Immunol. 1999 83 548 52.
38. Nettis E Pannofino A Fanelli M Ferrannini A Tursi A. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm. Venereol. 2002 82 297 320.
39. Capella GL Grigerio E Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur. J. Dermatol. 2001 11 209 13.
40. Yanase DJ David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J. Am. Acad. Dermatol. 2001 44 89 93.
41. Ackerman L Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res. 1998 290 353 9.
42. Junghans V Gutgesell C Jung T Neumann C. Epidermal cytokines IL-1beta, TNF-alpha, and IL-12 in patients with atopic dermatitis: response to application of house dust mite antigens. J. Invest. Dermatol. 1998 111 1184 8.
43. Jacobi A Antoni C Manger B Schuler G Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2005 52 522 6.
44. Chan JL Davis-Reed L Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 2004 3 315 18.
45. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J. Am. Acad. Dermatol. 2003 49 160 1.
46. Kagi MK Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody in a patient with severe chronic atopic dermatitis. Br. J. Dermatol. 2001 145 350 1.
47. Prussin C Griffith DT Boesel KM Lin H Foster B Casale TB. Omalizumab treatment downregulates dendritic cell FcεRI expression. J. Allergy Clin. Immunol. 2003 112 1147 54.
48. Lanier BQ Corren J Lumry W Liu J. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 2003 91 154 9.
49. Walker S Monteil M Phelan K Lasserson TJ Walters EH. Anti-IgE for chronic asthma. Cochrane Database Syst. Rev. 2003 3 CD003559.
50. Casale TB Condemi J LaForce C Nayak A Rowe M Watrous M et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001 286 2956 67.
51. Chervinsky P Casale T Townley R Tripathy I Hedgecock S Fowler-Taylor A Shen H Fox H. Omalizumab, an anti-IgE antibody, in treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2003 91 160 7.
52. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 354 1932 9.
53. Schmitt J Wozel G Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br. J. Dermatol. 2004 150 1182 5.
54. Novak N Bieber T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 2003 112 252 62.
55. Renz H Jujo K Bradley L Domenico J Gelfand EW Leung DY. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon gamma. J. Invest. Dermatol. 1992 99 403 8.
56. Boguniewicz M Jaffe HS Izu A Sullivan MJ York D Geha RS Leung DY. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am. J. Med. 1990 88 365 70.
57. Jang IG Yang JK Lee HJ Yi JY Kim HO Kim CW Kim TY. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 2000 42 1033 40.
58. Hanifin JM Schneider LC Leung DY Ellis CN Jaffe HS Izu AE et al. Recombinant interferon gamma therapy for atopic dermatitis. J. Am. Acad. Dermatol. 1993 28 189 97.
59. Reinhold U Kukel S Brzoska J Kreysel HW. Systemic interferon gamma treatment in severe atopic dermatitis. J. Am. Acad. Dermatol. 1993 29 58 63.
60. Stevens SR Hanifin JM Hamilton T Tofte SJ Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch. Dermatol. 1998 134 799 804.
61. Schneider LC Baz Z Zarcone C Zurakowski D. Longterm therapy with recombinant interferon-gamma for atopic dermatitis. Ann. Allergy Asthma Immunol. 1998 80 263 8.
62. Noh GW Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-γ therapy in atopic dermatitis. Allergy 1998 53 1202 7.
63. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin. Exp. Dermatol. 2001 26 127 31.
64. Sewell WA Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002 107 387 93.
65. Spahn JD Leung DY Chan MT Szefler SJ Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J. Allergy Clin. Immunol. 1999 103 421 6.
66. Samuelsson A Towers TL Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 484 6.
67. Jolles S Hughes J Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br. J. Dermatol. 2000 142 551 4.
68. Gelfand EW Landwehr LP Esterl B Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin. Exp. Immunol. 1996 104 S61 6.
69. Noh G Lee KY. Intravenous immunoglobulin in steroid-resistant atopic dermatitis. J. Korean Med. Sci. 1999 14 63 8.
70. Paul C Lahfa M Bachelez H Chevret S Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br. J. Dermatol. 2002 147 518 22.
71. Jolles S Sewell C Webster D Ryan A Heelan B Waite A Rustin M. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm. Venereol 2003 83 433 7.
72. Jolles S Hill H. Management of aseptic meningitis secondary to intravenous immunoglobulin. BMJ 1998 316 936.